The Exciting New Field of HER2-Low Breast Cancer Treatment

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

(2021) Francesco Schettini et al.   npj Breast Cancer

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

(2020) Barbara Pistilli et al.   JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

(2019) Gabriel Rinnerthaler et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

(2019) Filippo Montemurro et al.   EUROPEAN JOURNAL OF CANCER

Pertuzumab in HER2-positive early breast cancer: current use and perspectives

(2019) Daniel Eiger et al.   Future Oncology

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

(2019) Otto Metzger Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.

(2019) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine

(2019) Vadim Le Joncour et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

(2019) Louis Fehrenbacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

(2018) Cecile A.W. Geuijen et al.   CANCER CELL

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

(2018) S Loi et al.   CANCER RESEARCH

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

(2018) Neelima Denduluri et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

(2018) Luca Gianni et al.   LANCET ONCOLOGY

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.

(2018) Erika Paige Hamilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

(2017) Denis Collins et al.   PLoS One

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases

(2016) Silvia Giuliani et al.   VIRCHOWS ARCHIV

Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer

(2015) Holm Eggemann et al.   ENDOCRINE-RELATED CANCER

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

(2015) M. M. C. van der Lee et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis

(2014) Véronique Diéras et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

(2014) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

The immune system and response to HER2-targeted treatment in breast cancer

(2014) Giampaolo Bianchini et al.   LANCET ONCOLOGY

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria

(2013) Kurt A. Schalper et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

(2013) S. Ithimakin et al.   CANCER RESEARCH

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis

(2013) Hedyeh Shafi et al.   JOURNAL OF CLINICAL PATHOLOGY

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

(2012) Valentina Rossi et al.   ONCOLOGIST

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

(2010) Kathleen A. Cronin et al.   CANCER INVESTIGATION

HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

(2010) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer

(2009) Michael Z. Gilcrease et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2009) L. C. Benavides et al.   CLINICAL CANCER RESEARCH

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE